These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19917362)

  • 21. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production.
    Sido B; Dengler TJ; Otto G; Zimmermann R; Müller P; Meuer SC
    Eur J Immunol; 1998 Apr; 28(4):1347-57. PubMed ID: 9565375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
    van Hartingsveldt B; Nnane IP; Bouman-Thio E; Loza MJ; Piantone A; Davis HM; Petty KJ
    Br J Clin Pharmacol; 2013 May; 75(5):1289-98. PubMed ID: 23043368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD56(bright) natural killer cells expand and contract irrespective of CD25 antibody treatment in kidney allograft recipients.
    Zenhaeusern G; Hönger G; Gasser O; Steiger J; Schaub S; Hess C
    Scand J Immunol; 2009 May; 69(5):465-7. PubMed ID: 19508378
    [No Abstract]   [Full Text] [Related]  

  • 28. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.
    Vieira CA; Agarwal A; Book BK; Sidner RA; Bearden CM; Gebel HM; Roggero AL; Fineberg NS; Taber T; Kraus MA; Pescovitz MD
    Transplantation; 2004 Feb; 77(4):542-8. PubMed ID: 15084932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody.
    Cosimi AB; Delmonico FL; Wright JK; Wee SL; Preffer FI; Jolliffe LK; Colvin RB
    Surgery; 1990 Aug; 108(2):406-13; discussion 413-4. PubMed ID: 2382234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study of single-dose of recombinant humanized anti-CD3 monoclonal antibody injection in kidney transplant recipients].
    Huang HF; Wu JY; Shou ZF; Zhang JG; Cheng XJ; Liu GJ; Shentu JZ; Wu LH; Li J; Zhou B; Chen JH
    Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(8):516-9. PubMed ID: 21418850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
    Delbaldo C; Raymond E; Vera K; Hammershaimb L; Kaucic K; Lozahic S; Marty M; Faivre S
    Invest New Drugs; 2008 Feb; 26(1):35-43. PubMed ID: 17876527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with stroke.
    Cramer SC; Abila B; Scott NE; Simeoni M; Enney LA;
    Stroke; 2013 May; 44(5):1337-42. PubMed ID: 23471268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients.
    Kovarik JM; Rawlings E; Sweny P; Fernando O; Moore R; Griffin PJ; Fauchald P; Albrechtsen D; Sodal G; Nordal K; Amlot PL
    Transpl Int; 1996; 9 Suppl 1():S32-3. PubMed ID: 8959785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
    Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
    N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.
    Busse WW; Katial R; Gossage D; Sari S; Wang B; Kolbeck R; Coyle AJ; Koike M; Spitalny GL; Kiener PA; Geba GP; Molfino NA
    J Allergy Clin Immunol; 2010 Jun; 125(6):1237-1244.e2. PubMed ID: 20513521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
    Stenger EO; Chiang KY; Haight A; Qayed M; Kean L; Horan J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1845-52. PubMed ID: 26095669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.